MEET THE HISTOINDEX MANAGEMENT TEAM
Mr SIM Giok LakChairman, Board of Directors
Mr Sim founded Zicom Group in 1978 and is its Group Chairman and Managing Director. He is an experienced entrepreneur and knowledgeable business executive with expertise in public accounting, corporate development, financial and industrial management and international trade.
Mr Sim has been appointed as a Board member to SPRING, and chairs the Grant Appeal Panel and Growth Enterprise Panel. He is also a strategic advisor to the Diagnostic Development Hub and Singapore National Eye Center Incubation Board. Additionally, he is also on the Board of Governors, UOB-SMU Asian Enterprise. In 2008, he was the recipient of the Ernest & Young Entrepreneur of the Year (Industrial Products) award in Singapore.
Mr Sim qualified as an accountant in 1967. He is Fellow of the Australian Society of Certified Practising Accountants and Fellow of the Institute of Certified Public Accountants, Singapore.
Other Appointments: Chairman, Zicom Group
Mr SIM Kok HweeDirector, Board of Directors
Kok Hwee is an experienced corporate and operations leader with the Zicom Group, having assumed various responsibilities. His corporate responsibilities include banking relationships, treasury management, mergers and acquisitions, strategic partnerships and fund raising. Operationally, he has led group wide implementations of the ISO Quality Management Systems and also Enterprise Resource Planning Systems to optimize business performance.
As the Chief Executive Officer of ZIG Ventures Pte. Ltd. (formerly known as Zicom MedTacc), his focus is to co-invest with SPRING into promising early stage medtech companies. Apart from leveraging on the precision engineering and manufacturing infrastructure of the group, Kok Hwee leads a team of healthcare commercialization professionals to proactively build capabilities within the portfolio companies and to forge strategic partnerships with the global healthcare ecosystem.
Kok Hwee has a Masters of Science Degree in Financial Engineering from Columbia University, New York, USA and a Bachelor of Science Degree in Industrial and Operations Research from the University of Michigan, Ann Arbor, USA (Magna Cum Laude).
Other Appointments: Executive Director, Zicom Group; Chief Executive Officer, ZIG Ventures Pte. Ltd.
Dr Gideon HOCo-founder & Chief Executive Officer (CEO)
An A*STAR National Science scholar (fellowship), Gideon has been involved in bio-imaging development and research for the past 13 years, with added experience in project and operations management. He has four filed patents, and published multiple journal articles in medical imaging, lasers and optics.
In August 2010, Gideon co-founded HistoIndex as a spin-off from the Institute of Bioengineering and Nanotechnology (IBN) at the Agency for Science, Technology and Research (A*STAR), to develop and commercialize the world’s first fully automated, quantitative, stain-free imaging system and gain a first-mover advantage in global healthcare markets. As the CEO, Gideon sets the company’s overall corporate, commercial and marketing strategies to drive business growth and market shares.
With his leadership, the laser-based medical imaging systems – Genesis® and Laennec® – were successfully developed by the company and are currently being used for academic, clinical and commercial research in major universities, hospitals and contract reference facilities around the world, including the United States, Europe, China, Australia and Singapore.
Dr Dean TAICo-founder & Chief Scientific Officer (CSO)
As the CSO of HistoIndex, Dr. Dean Tai is responsible for the strategic product development and research collaboration with clinical key opinion leaders globally.
Together with his HistoIndex co-founder, Dr. Gideon Ho, Dean completed prototyping and manufacturing of products for HistoIndex in Singapore and Europe and successfully implemented the products in Singapore, China, Taiwan, and USA. He also established multi-centre clinical trials for the company’s inventions with global clinical key opinion leaders, and successfully coordinated pre-clinical and started clinical validation in Singapore.
Furthermore, Dean established the world’s first stain-free imaging database for fibrosis diseases study in chronic liver and kidney diseases, and implemented it in several countries across Asia and Europe. With his guidance, HistoIndex won the BioSpectrum Asia Pacific Bioscience Industry Emerging Company of the Year Award in 2012.
Mr Paddy LIANGChief Operating Officer (COO)
With 15 years’ broad-based engineering and manufacturing experience, Paddy understands how each part of an operation functions on a deep level. Data-driven and results-oriented, Paddy always looks out for new ways to improve operations and elevate best practices.
Also helming the Product Development portfolio at HistoIndex, Paddy sets the strategic direction for the operations and leads the employees who design and manufacture the company’s innovations. Since joining HistoIndex in 2013, Paddy has localised production from Dublin, Ireland to Singapore and streamlined the manufacturing process, including Engineering, Supplier Management and Environment, Health and Safety (EHS). Under Paddy’s direction, the department focuses on developing a high-performance culture that empowers employees to achieve manufacturing excellence.
Paddy also leads HistoIndex’s Regulatory Affairs department, which is responsible for regulatory approval, quality management as well as market-entry strategies. Paddy implemented the Quality Management System (QMS) at HistoIndex and obtained the ISO13485 certification in 2015.
Dr TENG XiaoChief Technology Officer (CTO) & China Subsidiary Chief Operating Officer (COO)
Dr Teng Xiao received his Ph.D. in Computer Engineering from Nanyang Technological University and B.Eng in Software Engineering from Zhejiang University. Since joining HistoIndex in 2013, Xiao has designed and developed core image processing and artificial intelligence algorithms for the company’s proprietary analysis software.
In 2014, Xiao helped the company found its fully owned subsidiary, Hangzhou Choutu Tech Co. Ltd. in China, and he now additionally leads Choutu’s daily operations. Under Xiao’s guidance, his team adapted clinically validated algorithms for preclinical models applications as well, and completed dozens of preclinical studies sponsored by world’s leading biopharmas, CROs and research institutes. Xiao also leads the algorithm development of new organ applications.
HistoIndex Scientific Advisory Board
Professor Stephen Harrison
Medical Director, Pinnacle Clinical Research, San Antonio, Texas, USA
Visiting Professor of Hepatology, Radcliffe Department of Medicine, University of Oxford, UK
Professor Quentin Anstee
Professor of Experimental Hepatology; Consultant Hepatologist, Institute of Cellular Medicine,
Newcastle University, UK
Honorary Consultant Hepatologist, Liver Unit, Freeman Hospital, Newcastle, UK
Professor Arun Sanyal
Professor, Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition,
Virginia Commonwealth University, Virginia, USA
President, Chair and Chief Medical Officer, Sanyal Biotechnology
Professor Wei Lai
Professor of Hepatology & Medicine; Director, Peking University Hepatology Institute, Beijing, China
Chief at Department of Hepatology, Peking University People’s Hospital, Beijing, China
Professor Jacob George
Robert W Storr Chair of Hepatic Medicine,
Professor of Gastroenterology and Hepatic Medicine,
Faculty of Medicine, University of Sydney, Australia
Director, Storr Liver Centre, The Westmead Institute for Medical Research;
Head, Department of Gastroenterology & Hepatology, Westmead Hospital and Sydney West Local Health District - Obesity-related Liver Disease and Cancer Group